SRPT came out with big news (in their case FDA approval) and within days announced a huge secondary offering...which was priced $3.50 higher than where the stock closed just prior to the announcement. Shares have continued to rally on the news - up around 100% in the past week. The point is - a secondary isn't always a bad thing. With any luck SGLB will follow a similar path.